LEGN241115P50000
- 7.60
- 0.000.00%
Legend Biotech Newsroom
BMO Capital Maintains Legend Biotech(LEGN.US) With Buy Rating, Maintains Target Price $90
Strategic Growth and Promising Prospects Drive Buy Rating for Legend Biotech
H.C. Wainwright Maintains Legend Biotech(LEGN.US) With Buy Rating, Maintains Target Price $73
Scotiabank Maintains Legend Biotech(LEGN.US) With Buy Rating, Maintains Target Price $76
A Quick Look at Today's Ratings for Legend Biotech(LEGN.US), With a Forecast Between $73 to $94
Legend Biotech (LEGN) Gets a Buy From Scotiabank
Legend Biotech Price Target Maintained With a $73.00/Share by HC Wainwright & Co.
Legend Biotech Analyst Ratings
Positive Outlook and Buy Rating for Legend Biotech Driven by CARVYKTI's Strong Performance and Market Edge
Jefferies Maintains Legend Biotech(LEGN.US) With Buy Rating, Maintains Target Price $94
TD Cowen Maintains Legend Biotech(LEGN.US) With Buy Rating, Maintains Target Price $67
BMO Capital Maintains Legend Biotech(LEGN.US) With Buy Rating, Maintains Target Price $90
Redburn Initiates Legend Biotech at Buy With $86 Price Target
H.C. Wainwright Maintains Legend Biotech(LEGN.US) With Buy Rating, Maintains Target Price $73
Buy Rating for Legend Biotech: Strategic Expansion and Increased CARVYKTI Production Forecasted to Alleviate Supply Constraints and Drive Growth
Legend Biotech Analyst Ratings
A Quick Look at Today's Ratings for Legend Biotech(LEGN.US), With a Forecast Between $73 to $94
A Quick Look at Today's Ratings for Legend Biotech(LEGN.US), With a Forecast Between $73 to $90
Legend Biotech (LEGN) Receives a Hold From William Blair
Legend Biotech Analyst Ratings